Regenerative Therapies for Neurological Disorders

1. Regenerative Therapiesfor Neurological Disorders

2. Company Overview

3. Company Background Mission Statement SanBio develops regenerative therapies addressing unmet medical needs and creating value for stakeholders. • Quick Facts • Clinical-stage regenerative medicine company • Founded in 2001 • Headquartered in Mountain View, Calif. • Funding to Date: $53 million • 35 patents issued, 41 patents pending

4. Japan/U.S. Hybrid Innovation Innovative Science & Technology Clinical Trial & Development Innovative Business Infrastructure Financial Support

5. Neurological Disorders: Market Size Neurological Disorder Sector is Growing Rapidly, Faster Than Other Markets We are researching the product sales and will add

6. Potential Market Value Valuation Summary

7. Competitive Overview • Neural Deficit Recovery™ (NDR) patented drug discovery platform • Bone marrow-derived cells • Industrial scale expansion • Therapeutic potential

8. Management Team Keita Mori, MBA Co-CEO, Chairman, Co-Founder Placeholder: Headshot Toru Kawanishi Co-CEO, Co-Founder Placeholder: Headshot Michael P. McGrogan, Ph.D. Senior Vice President, Production Development Placeholder: Headshot Damien Bates MD, PhD, FRACS, MBA Chief Medical Officer Placeholder: Headshot

9. Advisors Scientific Advisory Board Senior Advisors

10. Partnerships • Clinical Trial Partners • Corporate Partners • Innovation Awards

11. Approach to Brain Regeneration Allogeneic Cell Transplant Donor bone marrow stem cells are harvested Regenerative effect on recipient cells Brain & body function restored

12. NDR™Technology Platform Products (“Cells-in-a-bottle”) Production Neural Deficit Recovery™ NDR™ Technology SB623 SB618 Bone Marrow SB308 . . .

13. Product Pipeline

14. Damien – Can you recommend an image for SB618? • Bone Marrow-Derived Regenerative Cell Medicines Bone Marrow Derived Cells SB623 SB618 SB308 Bone Marrow-Derived Muscle Regenerative Cells Bone Marrow-Derived Neuroregenerative Cells Enhanced Marrow Stromal Cells (eMSC) Different image Stroke, TBI, SCI, Retinal Disease, PD, AD, etc. Multiple Sclerosis, Peripheral Nerve, SCI, etc. Muscle Dystrophy, etc. P-1/2 Nonclinical Research

15. Indications Overview

16. SB623

17. Therapy Overview • Developed as treatment for chronic neurological deficits – stable stroke, advanced Parkinson’s disease, traumatic brain injury • Reverses neural damage when injected into neural tissue • Single allogeneic donor cell can be used to treat thousands of patients. • Shown to restore function to damaged neurons associated with stroke, spinal cord injury and Parkinson's disease SB623 Cells

18. Manufacturing Process & Product Preparation Scalable Production Methods Reduced to Practice • Cells are expanded, formulated and cryopreserved in vials stored in vapor phase of liquid nitrogen • Final product is a sterile frozen suspension containing at least 10 million viable cells per mL in a cryovial • Shipped to clinical sites using a Dry Nitrogen Cryo shipper with adsorbed liquid nitrogen • Cells will grow with a doubling time of 3 to 4 days after thaw

19. Damien – Please note that we will have our creative team rework this slide to make it look more polished Multiple Modes of Action Trophic Factors Angiogenesis SB623 Modes of Action Extracellular Matrix Stimulating Migration Anti-inflammation

20. Product Characteristics Bulk Substance Specifications

21. Product Characteristics Drug Product Specifications

22. Loss of NICD with Continued Passages Disappearance of The Plasmid During Expansion (prior to phase 2) Plasmid pN-2 was measured using qPCR and expressed as copies per diploid genome. Passage number is represented as P1, P2, etc. The negative control is buffer alone. Lanes 1, 2, 5 and 6 are unactivated/unstabilized negative controls. Lanes 3 and 4 show activated and stabilized samples and indicate the location of the endogenous NICD. Lane 7 shows high levels of NICD protein 3 days post transfection. Lane 8 shows no detectable NICD in the final product.

23. Transient Transfection with NICD Causes Epigenetic Changes CpG Methylation Status of 5 Different Genes for 3 Donors

24. Homogeneity and Identity of SB623 Cells Cells are Positive for MSC Markers and Negative for Hematopoietic Markers

25. Proteomic Analysis of the Extracellular Matrix Characterization of the ECM Produced by SB623

26. Extracellular Matrix Produced by Bone Marrow Stromal Cells ECM Promotes Neural Growth

27. Extracellular Matrix Produced by Bone Marrow Stromal Cells Supports Growth of Different Neural Cell Types

28. Comparison of The Neuropoietic Activity Derived ECM Supports Nestin Growth; Mediated by TGM2

29. Human Mesenchymal Stromal Cells and Their Derivative Multiple Growth Factors Released Placeholder: We are simplifying the table per your notes and will add in

30. Human Mesenchymal Stromal Cells and Their Derivative Reduces Cell Death In Vitro Model Ischemia

31. Quantitative Microplate Assay for Studying MSCs Promote Neural Cell Growth and Differentiation

32. Comparison of The Neuropoietic Activity SB623 Promotes More Neural Cell Growth and Differentiation Than MSCs

33. Comparison of The Neuropoietic Activity SB623 Action Mediated by FGF2 and BMP4

34. Comparing The Angiogenic PotencySB623 and MSCs Secrete Proangiogenic Factors

35. Comparing The Angiogenic PotencySB623 Promotes More Branching in Aortic Ring Assay

36. Comparing The Immunosuppressive Potency Decreases Cell Mediated Immune Response

37. Effect on Peripheral and Nervous System Innate Immune Cells SB623 Cells Reduce The Percentage of Pro-Inflammatory Peripheral Blood Monocytes

38. Comparing The Immunosuppressive Potency SB623 Induces Regulatory T Lymphocytes

39. Comparing The Immunosuppressive Potency SB623 Inhibits Differentation of Monocytes to Dendritic Cells

40. Stem Cell Recruitment of Newly Formed Host Cells SB623 Supports Robust Migration and Proliferation of Endogenous Stem Cells in Traumatic Brain Injury Model

41. Effect of SB623 on Neural Progenitor Cell Migration Dose Response of SB623 Conditioned Medium on NPC Migration

42. Safety Cells Are Not Tumorigenic SB623 Cells Do Not Exhibit Signs of Tumorigenic Transformation Absence of Growth on Brain Slices

43. Safety Transient Persistence of SB623 Cells In Vivo and No Migration Away From Site of Implantation Rapid Disappearance of SB623 Cells In Vivo

44. Safety SB623 Cells Have Limited Differentiation Potential Differentiation Potential of MSCs and SB623

45. Clinical Trials and Data

46. Damien – Please note that we will have our creative team rework this slide to make it look more polished Development Stages SB308 Muscle Degeneration

47. SB623: Clinical Trial Overview Stable Stroke Traumatic Brain Injury Dry AMD Retinitis Pigmentosa Parkinson’s Disease Spinal Cord Injury Alzheimer’s Disease

48. SB623: Stroke Preclinical Program SB623 Tested in Chronic Stroke Rat Model to Determine Functional Recovery

49. SB623: Stroke Phase 1 & 2 Clinical Trials Overall Design • Open Label • 18 Stroke Patients • 6 Mo. Efficacy, 2-Year Follow-Up Patient Population • 6-36 Months Post-Ischemic Stroke • Stable Deficits • Moderate to Severe Patients Endpoints • Safety • Efficacy: Motor, Sensory, Cognitive • Brain Activity by PET Trial Sites 12 Patients Enrolled & Good Safety

50. SB623: Stroke Phase 1 & 2 Clinical Trials Approach Damien – We’ve reviewed all the materials and can’t find a better image. We can pull a stock image and then add the arrows to the sites if you’re okay with that Stereotactic Frame Positioning Needle Tracks for Cell Implementation and Suggest Implant Sites